7 ms·
What's needed is a new payment model for anti-infectives. This already happens at a small scale with grants from institutions like BARDA. The DOD of also does
by refurb 7y ago
What's needed is a new payment model for anti-infectives. This already happens at a small scale with grants from institutions like BARDA. The DOD of also does this for vaccines for biological weapons like anthrax where there is a high likelihood the drug will never be used, but a vaccine is needed because if there is an outbreak, the consequences are severe.
Basically, rather than paying for drugs on a per unit basis, you pay a lump sum for access to the drug. This solves the issues of spending $100M to develop a new treatment for some disease where there is never a outbreak and you cover none of the cost of R&D.
There have been ideas to have X-Prizes for new antibiotics. Discover a new drug for a anti-biotic resistant infection? Great, here is $500M as long as you agree to produce as much drug as needed for free or some nominal cost.
- JumpCrisscross 7y ago> Great, here is $500M as long as you agree to produce as much drug as needed for free or some nominal cost Why not give $5bn (or whatever the NPV of the drug at a reasonable rate of return might be) in exchange for releasing the drug into the public domain? Then any number of generics manufacturers could be contracted to maintain a stockpile.
- refurb 7y agoSure you could do that, but manufacturing drugs isn't as simple as hitting a switch - the infrastructure needed along with the scientific expertise is sometimes hard to replicate.
- markdown 7y agoThe infrastructure and expertise exists in India, and they'll gladly manufacture drugs at a cost that the developing world can afford.
- refurb 7y agoDepends on the drug. Small molecules, sure? Complex biologics? Even other large pharma companies can have challenges making those.
- newyankee 7y agoCould you give an example of what makes complex biologics difficult, is it the actual process or just the fact that IP is not shared easily and the hurdles to get licensing in place.
- hobofan 7y agoA quick google gives you a good rough summary[0]. The quote that summarizes it the best would be: > for biologics, "the product is the process." [0]: https://archive.bio.org/articles/how-do-drugs-and-biologics-differ https://archive.bio.org/articles/how-do-drugs-and-biologics-...
- vikramkr 7y agoBecause they're produced by biological processes (grow cells that produce the protein and purify it), you don't really have atom level control and replicability of the end product - there's a lot of variability. So, the exact process that it's produced with is regulated and tracked, and there will be IP over that process as well. You can see the impacts of that in how much harder biosimilars are to develop than generics
- sfifs 7y agoIndian manufacturers actually make several complex cancer therapies under the new compulsory licensing law that are made to my knowledge nowhere else except the US. The original manufacturer refused to launch in India. (Source: a colleague from another country where the manufacturer also made the drug unavailable asked to have the drugs procured from India) Edit: the drug was Nexavar by Bayer. The CEO was quoted as saying "No, because we did not develop this product for the Indian market, let’s be honest. We developed this product for Western patients who can afford this product, quite honestly". Recently it seems the Indian courts also allowed export licenses for the drug to other markets where Bayer similarly refused to launch - sadly after the relative of my colleague passed away - at least partially from the delay in procuring the drug.
- JumpCrisscross 7y ago> the infrastructure needed along with the scientific expertise is sometimes hard to replicate Then the original developer can be the manufacturer. But no need to add hurdles.
- _bxg1 7y ago> Basically, rather than paying for drugs on a per unit basis, you pay a lump sum for access to the drug. Hmm... a system where uncommon but extreme spikes in the cost of care are artificially distributed so that an entire society can bear them as a group... that sounds oddly familiar...
- refurb 7y agoArtificially distributed? It's no different than paying a drug maker a ton of money to make the drugs and stockpile them. And at any rate, the alternative is what we have now - no drugs to treat these diseases.
- _bxg1 7y agoI wasn't using the word "artificial" in a negative sense; I was pointing out that this is a narrow example of socialized healthcare and why it's beneficial.
- refurb 7y agoGotcha. As an aside, the "netflix model" for drug payments is already a reality in Louisiana. Basically the drug maker and state government negotiated a payment for enough hepatitis C drugs to cure everyone in the state.[1] [1]http://ldh.la.gov/index.cfm/newsroom/detail/5181 http://ldh.la.gov/index.cfm/newsroom/detail/5181
- 7y ago
- tus88 7y ago> Discover a new drug for a anti-biotic resistant infection? Great, here is $500M as long as you agree to produce as much drug as needed for free or some nominal cost. If you were going to develop the drug at your own cost with no subsidy for failure, why settle for 500M? Why not do it on your kwn merit and reap billions instead? And keep all the IP.
- vikramkr 7y agoIn other disease areas that makes sense, but for anti-biotics that 500 million is more than you'd be able to make on the market. Especially if the antibiotic is really good - the better it is the less it will be used since we want to prevent resistance developing to our best drugs. That 500 million might be necessary to make the development be worth it.
- _jal 7y agoWhat's needed is for the NIH to get in to the drug manufacturing business, start making generics and vaccines itself. A huge amount of their research already is directly responsible for private industry profits; they can be happy with that freebie. But for things like vaccines in emergencies and insulin, if this be socialism; let's make the most of it.
- Aunche 7y ago> Discover a new drug for a anti-biotic resistant infection? Great, here is $500M as long as you agree to produce as much drug as needed for free or some nominal cost. Most AR bacteria can be killed by trying different antibiotics. Sure they can mutate to something more dangerous, but it doesn't make sense to make drugs for bacteria that don't even exist yet. There are too many variables to account for.
- Proven 7y agoNo. What's needed is that governments stop interfering with free market so that those who want to invest in this underserved market can make more money than those who invest in other markets.